Klebsiella pneumoniae Antimicrobial Drug Resistance, United States, 1998–2010

We studied antimicrobial-resistant Klebsiella pneumoniae for 1998–2010 by using data from The Surveillance Network. Susceptibility results (n = 3,132,354) demonstrated significant increases in resistance to all antimicrobial drugs studied, except tetracycline. Cross-resistance among carbapenem-resistant K. pneumoniae was lower for tetracycline and amikacin.

[1]  A. MacGowan,et al.  Pharmacokinetics and pharmacodynamics of the tetracyclines including glycylcyclines. , 2006, The Journal of antimicrobial chemotherapy.

[2]  John Quale,et al.  Emergence of KPC-Possessing Klebsiella pneumoniae in Brooklyn, New York: Epidemiology and Recommendations for Detection , 2005, Antimicrobial Agents and Chemotherapy.

[3]  R. Humphries,et al.  Successful treatment of pan-resistant Klebsiella pneumoniae pneumonia and bacteraemia with a combination of high-dose tigecycline and colistin. , 2010, Journal of medical microbiology.

[4]  J. Patel,et al.  Regional Dissemination of KPC-Producing Klebsiella pneumoniae , 2009, Antimicrobial Agents and Chemotherapy.

[5]  Yehuda Carmeli,et al.  Carbapenem-resistant Enterobacteriaceae: a potential threat. , 2008, JAMA.

[6]  J. Karlowsky,et al.  In Vitro Antimicrobial Resistance of Urinary Escherichia coli Isolates among U.S. Outpatients from 2000 to 2010 , 2012, Antimicrobial Agents and Chemotherapy.

[7]  P. Nordmann,et al.  Plasmid-Mediated Carbapenem-Hydrolyzing β-Lactamase KPC in a Klebsiella pneumoniae Isolate from France , 2005, Antimicrobial Agents and Chemotherapy.

[8]  F. Baquero,et al.  In vitro susceptibilities of aerobic and facultatively anaerobic Gram-negative bacilli isolated from patients with intra-abdominal infections worldwide: 2004 results from SMART (Study for Monitoring Antimicrobial Resistance Trends). , 2006, The Journal of antimicrobial chemotherapy.

[9]  Neil Gupta,et al.  Carbapenem-resistant Enterobacteriaceae: epidemiology and prevention. , 2011, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[10]  Iraida E. Robledo,et al.  Guidance for control of infections with carbapenem-resistant or carbapenemase-producing Enterobacteriaceae in acute care facilities. , 2009, MMWR. Morbidity and mortality weekly report.

[11]  M. Marsilio,et al.  Antimicrobial resistance in key bloodstream bacterial isolates: electronic surveillance with the Surveillance Network Database--USA. , 1999, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[12]  C. Nicolaou,et al.  Tigecycline in the treatment of infections from multi-drug resistant gram-negative pathogens. , 2009, The Journal of infection.

[13]  Ronald N. Jones,et al.  Summary trends for the Meropenem Yearly Susceptibility Test Information Collection Program: a 10-year experience in the United States (1999-2008). , 2009, Diagnostic microbiology and infectious disease.

[14]  R. Weinstein,et al.  Emergence and rapid regional spread of Klebsiella pneumoniae carbapenemase-producing Enterobacteriaceae. , 2011, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[15]  J. Bartlett,et al.  The epidemic of antibiotic-resistant infections: a call to action for the medical community from the Infectious Diseases Society of America. , 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.